ZA848619B - Treatment of hypertension,compounds and compositions for antihypertension and diuresis - Google Patents

Treatment of hypertension,compounds and compositions for antihypertension and diuresis

Info

Publication number
ZA848619B
ZA848619B ZA848619A ZA848619A ZA848619B ZA 848619 B ZA848619 B ZA 848619B ZA 848619 A ZA848619 A ZA 848619A ZA 848619 A ZA848619 A ZA 848619A ZA 848619 B ZA848619 B ZA 848619B
Authority
ZA
South Africa
Prior art keywords
thiazide
salts
diuresis
achieve
antihypertension
Prior art date
Application number
ZA848619A
Other languages
English (en)
Inventor
Ronald B Miller
Stewart Thomas Leslie
Peter Hofer
Alfred Halpern
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24234891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA848619(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ZA848619B publication Critical patent/ZA848619B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
ZA848619A 1983-12-09 1984-11-05 Treatment of hypertension,compounds and compositions for antihypertension and diuresis ZA848619B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/559,755 US4898729A (en) 1983-12-09 1983-12-09 Treatment of hypertension, compounds and compositions for antihypertension and diuresis

Publications (1)

Publication Number Publication Date
ZA848619B true ZA848619B (en) 1985-06-26

Family

ID=24234891

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA848619A ZA848619B (en) 1983-12-09 1984-11-05 Treatment of hypertension,compounds and compositions for antihypertension and diuresis

Country Status (17)

Country Link
US (1) US4898729A (xx)
EP (1) EP0154009B1 (xx)
JP (4) JPS60139620A (xx)
AT (1) ATE91416T1 (xx)
AU (2) AU564078B2 (xx)
CA (1) CA1279575C (xx)
DE (1) DE3486177T2 (xx)
DK (1) DK586784A (xx)
FI (1) FI844593L (xx)
GR (1) GR81209B (xx)
IE (1) IE60713B1 (xx)
IL (1) IL73422A0 (xx)
IN (1) IN162797B (xx)
MX (1) MX156438A (xx)
NZ (1) NZ210056A (xx)
PT (1) PT79604B (xx)
ZA (1) ZA848619B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502816A (ja) * 1986-05-02 1989-09-28 ジーエーエフ・コーポレーション 水溶性ポリビニルラクタムー薬剤複合体
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US5132296A (en) * 1987-08-14 1992-07-21 Cherksey Bruce D Membrane NA+ channel protein and related therapeutic compounds
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US6894071B2 (en) 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
AU2007213476B2 (en) * 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
KR101368997B1 (ko) * 2009-10-20 2014-03-03 재단법인 의약바이오컨버젼스연구단 벤즈티아지드를 유효성분으로 함유하는 항암용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL247297A (xx) * 1959-01-14
US3781430A (en) * 1962-10-30 1973-12-25 Merck & Co Inc Diuretic formulations
FR3608M (fr) * 1964-02-03 1965-10-11 Merck & Co Inc Compositions diurétiques.
NL7508856A (nl) * 1974-08-16 1976-02-18 Merck & Co Inc Werkwijze voor het bereiden van preparaten tegen hypertensie.
FR2314719A1 (fr) * 1975-04-11 1977-01-14 Roussel Uclaf Nouveau medicament notamment diuretique
GB1525296A (en) * 1975-08-04 1978-09-20 Geistlich Soehne Ag Antibacterial compositions
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
GB1509778A (en) * 1975-10-29 1978-05-04 Leo Pharm Prod Ltd Pharmaceutical composition and dosage units thereof
DE2638716A1 (de) * 1976-08-27 1978-03-02 Ici Gmbh Antihypertensiva
CA1120400A (en) * 1977-12-27 1982-03-23 Zola P. Horovitz Method of treating hypertension and medicaments therefor
CH639273A5 (de) * 1978-09-12 1983-11-15 Hoffmann La Roche Diuretische mittel.
DE3027392A1 (de) * 1980-07-17 1982-02-04 Schering Ag, 1000 Berlin Und 4619 Bergkamen Synergistische kombination eines (beta) -rezeptorenblockers mit einem saluretikum
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
JPS5788117A (en) * 1980-11-21 1982-06-01 Smithkline Corp Gelatin capsule containing triamterene
JPS5933213A (ja) * 1982-07-27 1984-02-23 ミラン・フア−マスウ−テイカルズ・インコ−ポレイテイド 医薬組成物及びその製造方法
JPS5927812A (ja) * 1982-08-05 1984-02-14 Kotobuki Seiyaku Kk ニフエジピン製剤の製造方法
JPS5982314A (ja) * 1982-10-29 1984-05-12 インステイテユト・オルガニチエスコゴ・シンテザ・アカデミイ・ナウク・ラトビイスコイ・エスエスア−ル 抗菌性医薬組成物

Also Published As

Publication number Publication date
MX156438A (es) 1988-08-22
US4898729A (en) 1990-02-06
DK586784D0 (da) 1984-12-07
PT79604B (en) 1986-11-18
PT79604A (en) 1985-01-01
FI844593L (fi) 1985-06-10
CA1279575C (en) 1991-01-29
IN162797B (xx) 1988-07-09
EP0154009A1 (en) 1985-09-11
JPS60139620A (ja) 1985-07-24
JPH10152441A (ja) 1998-06-09
IE60713B1 (en) 1994-08-10
EP0154009B1 (en) 1993-07-14
ATE91416T1 (de) 1993-07-15
AU564078B2 (en) 1987-07-30
IE843148L (en) 1985-06-09
AU3641484A (en) 1985-06-13
JPH08253418A (ja) 1996-10-01
DK586784A (da) 1985-06-10
NZ210056A (en) 1989-01-06
FI844593A0 (fi) 1984-11-22
AU602899B2 (en) 1990-11-01
IL73422A0 (en) 1985-02-28
DE3486177T2 (de) 1994-03-10
DE3486177D1 (de) 1993-08-19
GR81209B (en) 1985-04-10
JPH09278655A (ja) 1997-10-28
AU7440287A (en) 1987-10-08

Similar Documents

Publication Publication Date Title
GR81209B (en) Treatment of hypertension, compounds and compositions for atnihypertension and diuresis
IE890868L (en) Anticalculus oral composition
KR870002828A (ko) 치석방지 구강 조성물, 그 제조방법 및 이를 사용한 치석 방지법
AU586166B2 (en) Anti-inflammatory compounds compositions containing them and processes for their preparation
NZ334537A (en) Two phase remineralising composition comprising a source of calcium ions and a source of phosphate ions with a water soluble polyphosphate salt
KR870008580A (ko) 항치석 치약
DE3460577D1 (en) Sodium salt of ursodeoxycholic sulphate
GEP20012390B (en) Benzonaphthyridines as Bronchial Therapeutics
MY118918A (en) Solid and semisolid compositions for reducing tooth erosion
MY130555A (en) Super absorbent polymer composition
CA2298645A1 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
IL134163A0 (en) Chromium/biotin treatment of type ii diabetes
EP0068453A3 (en) Compositions for treating kidney stones
NZ213197A (en) 2,3-dihydrobenzofuran-5-sulphonamide derivatives and pharmaceutical compositions
AU3081389A (en) Anticalculus oral compositions
WO1992013813A3 (en) Improved solubility compound fertilizer compositions
JPS57106618A (en) Anticancer agent consisting of polyprenyl compound
ES8305581A1 (es) Un procedimiento para la preparacion de una composicion de un polimero de poli-(arilen-eter-sulfona) sulfonado.
GB1511196A (en) Creatinine pyrolidonecarboxylate
DE3564423D1 (en) Purification of 4-fluoro-4'-hydroxy-benzophenone
Daelemans et al. Calcium Carbonate as Phosphate Binder in Patients on Low-Calcium Dialysate
KR960701644A (ko) 골다공증의 치료를 위한 방법 및 조성물(method and composition for treatment of osteoporosis)
FR2342726A1 (fr) Nouvelles compositions diuretiques
JPS57100916A (en) Prevention of solidification of glauber's salt
ES2023296A6 (es) Composicion oral antibacteriana y anti-placa.